About the Company
biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PHGE News
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the ...
Cystic Fibrosis Foundation Invests an Additional $5 Million in BiomX
The Cystic Fibrosis Foundation announced today that it has invested an additional $5 million in BiomX Inc. to support a Phase ...
Why BiomX Stock Is Surging Today
BiomX Inc. (AMEX:PHGE) shares are trading higher Wednesday after the company announced it has entered into a definitive ...
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of ...
BiomX Inc PHGE
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Merus, Gilead ink $1.5B+ deal; Biomx merges with Adaptive Phage
Merus NV added Gilead Sciences Inc. to its collaboration roster, entering a deal potentially worth more than $1.5 billion. While its previous agreements have focused primarily on bispecific antibodies ...
BiomX Buy Rating Justified by Merger Synergy, Enhanced Financial Stability, and Promising Clinical Trials
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on BiomX (PHGE – Research Report). The associated price ...
Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics
MILWAUKEE, March 7, 2024 /PRNewswire/ -- Ademi LLP is investigating BiomX (NYSE American: PHGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Adaptive ...
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage ...
BiomX Inc.
Huang's Nvidia, one of the top performing stocks over the last year, will issue what's expected to be a whopper of an earnings report on Wednesday. The standard deduction reduces the amount of ...
Loading the latest forecasts...